Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $22.8182.

ATEC has been the subject of a number of analyst reports. Loop Capital set a $25.00 target price on shares of Alphatec in a research note on Wednesday, December 10th. Morgan Stanley set a $23.00 price target on Alphatec in a report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research report on Monday, December 29th. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Alphatec in a research report on Monday, January 12th. Finally, TD Cowen restated a “buy” rating on shares of Alphatec in a research note on Tuesday, January 27th.

Insider Activity at Alphatec

In related news, EVP David Sponsel sold 60,425 shares of Alphatec stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $13.79, for a total transaction of $833,260.75. Following the sale, the executive vice president directly owned 349,500 shares in the company, valued at $4,819,605. This trade represents a 14.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Craig E. Hunsaker sold 37,358 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $14.71, for a total transaction of $549,536.18. Following the completion of the sale, the executive vice president directly owned 1,173,025 shares of the company’s stock, valued at approximately $17,255,197.75. This trade represents a 3.09% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 1,436,125 shares of company stock valued at $29,385,878 in the last quarter. Company insiders own 20.90% of the company’s stock.

Hedge Funds Weigh In On Alphatec

Hedge funds have recently made changes to their positions in the company. Creative Planning increased its position in shares of Alphatec by 0.9% during the third quarter. Creative Planning now owns 58,654 shares of the medical technology company’s stock worth $853,000 after purchasing an additional 534 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in Alphatec by 2.1% during the 3rd quarter. Valeo Financial Advisors LLC now owns 41,296 shares of the medical technology company’s stock worth $600,000 after buying an additional 846 shares during the last quarter. Norden Group LLC increased its position in Alphatec by 2.6% during the third quarter. Norden Group LLC now owns 36,676 shares of the medical technology company’s stock worth $533,000 after buying an additional 939 shares during the period. Arizona State Retirement System lifted its stake in Alphatec by 2.8% in the third quarter. Arizona State Retirement System now owns 34,603 shares of the medical technology company’s stock valued at $503,000 after buying an additional 949 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Alphatec by 8.8% in the second quarter. Ameritas Investment Partners Inc. now owns 11,845 shares of the medical technology company’s stock valued at $131,000 after acquiring an additional 955 shares during the period. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Alphatec Stock Down 0.2%

ATEC stock opened at $14.01 on Friday. The company’s 50 day moving average price is $16.86 and its 200 day moving average price is $17.10. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -14.75 and a beta of 1.01. Alphatec has a fifty-two week low of $8.81 and a fifty-two week high of $23.29. The company has a debt-to-equity ratio of 40.35, a quick ratio of 1.24 and a current ratio of 2.06.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Tuesday, February 24th. The medical technology company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The firm had revenue of $212.93 million for the quarter, compared to analyst estimates of $212.67 million. During the same quarter last year, the firm earned ($0.23) EPS. The company’s revenue was up 20.4% on a year-over-year basis. On average, equities research analysts anticipate that Alphatec will post -1.08 EPS for the current fiscal year.

Key Stories Impacting Alphatec

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Company reported stronger-than-expected Q4 performance on key metrics and reiterated its 2026 outlook, which supports the narrative of durable top-line growth and improving margins. Did ATEC’s Strong Q4 Beat and Reaffirmed 2026 Outlook Just Shift Alphatec Holdings’ Investment Narrative?
• Positive Sentiment: Analysts reiterated Buy ratings and raised or maintained price targets (Needham $25, H.C. Wainwright $24), which can provide upside support if guidance execution continues. Alphatec: Strengthening Earnings Leverage and Market Share Underscore Attractive Buy-Rated Risk/Reward Alphatec: Buy Rating Reaffirmed on Consistent Outperformance, Differentiated Technology, and Supportive Valuation
• Positive Sentiment: Management outlined a ~17% revenue growth target for 2026 while emphasizing improved profitability and cash flow — a forward-growth signal that investors tend to reward if delivery follows. Alphatec outlines 17-percent revenue growth target for 2026 while strengthening profitability
• Neutral Sentiment: Market write-ups and earnings-call highlights emphasize strong revenue growth and improved leverage, useful context for longer-term valuation but likely already partially priced in. Alphatec Holdings Inc (ATEC) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Post-earnings valuation pieces analyze upside vs. execution risk — helpful for investors sizing positions but not an immediate catalyst by itself. A Look At Alphatec Holdings (ATEC) Valuation After Better Than Expected Earnings And 2026 Outlook Reaffirmation
• Neutral Sentiment: Short-interest reports for late February show anomalous zero/NaN values and an effectively 0.0 days-to-cover figure — this appears to be a data/reporting issue and is unlikely to be a meaningful driver unless corrected. (internal short-interest entries)
• Negative Sentiment: An earnings-call transcript published by a third party shows a GAAP/adjusted EPS discrepancy (a reported miss on EPS vs. some market summaries showing an adjusted beat), which can create investor confusion and pressure near term until reconciliations are clarified. Alphatec Holdings, Inc. Q4 2025 Earnings Call Transcript

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.